Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2/Neu ICD Peptide-Based Vaccine in HER2+ Breast Cancer
NCT00343109Phase 2Completed
- Sponsor
- University of Washington
- Start
- Mar 2004
- Primary completion
- Jun 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HER-2/neu intracellular domain protein in breast cancer, sponsored by University of Washington. Started Mar 2004; status: completed.
02
Drugs
HER-2/neu intracellular domain protein
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00343109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343109.